Zacks.com on MSN15d
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
Nasdaq15d
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
Also, rival Novo Nordisk NVO announced disappointing data ... which showed that patients not on positive airway pressure (PAP) therapy taking Zepbound experienced 25 fewer breathing disruptions ...
Becker's ASC22d
GLP-1s driving up healthcare usage: 5 things to know
The rising use of GLP-1 medications, such as Novo Nordisk's Wegovy and Ozempic ... an uptick in GLP-1 use is facilitating a range of "crucial preventive care," including pap smears and colonoscopies.
STAT4d
They may be ‘miracle’ drugs, but obesity meds call for a team approach
The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...
CNBC on MSN17d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...
Pharmaceutical Technology15d
FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea
These studies evaluated Zepbound’s effectiveness in reducing breathing disruptions over the course of one year in adults with obesity, both with and without positive airway pressure (PAP) therapy ...